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Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency 
use as therapeutics. Here we identify 377 human monoclonal antibodies (mAbs) recognizing 
the virus spike, and focus mainly on 80 that bind the receptor binding domain (RBD). We 
devise a competition data driven method to map RBD binding sites. We find that although 
antibody binding sites are widely dispersed, neutralizing antibody binding is focused, with 
nearly all highly inhibitory mAbs (IC50<0.1µg/ml) blocking receptor interaction, except for 
one that binds a unique epitope in the N-terminal domain. Many of these neutralizing mAbs 
use public V-genes and are close to germline. We dissect the structural basis of recognition 
for this large panel of antibodies through X-ray crystallography and cryo-electron microscopy 
of 19 Fab-antigen structures. We find novel binding modes for some potently inhibitory 
antibodies and demonstrate that strongly neutralizing mAbs protect, prophylactically or 












A severe viral acute respiratory syndrome named COVID-19 was first reported in Wuhan, 
China in December 2019. The virus rapidly disseminated globally leading to the pandemic 
we are suffering, with over 100M confirmed infections and over 2.2M deaths 
(https://www.worldometers.info/coronavirus/). The causative agent, SARS-CoV-2, is a beta 
coronavirus, related to SARS-CoV-1 and MERS coronaviruses, which both cause severe 
respiratory syndromes.  
 
The sequence of SARS-CoV-2 was released in early January 2020 and this led to the 
mobilisation of an unprecedented international scientific response (Chen et al., 2020a). Over 
two hundred vaccine candidates are in development (Krammer, 2020) and 13 are in phase III 
clinical trials (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-
candidate-vaccines) with Novovax and Janssen having reported efficacy recently and 
Pfizer/BioNTech, Moderna and Oford-AstraZeneca having received, emergency use 
authorization (EUA) in a number of countries. 
 
Coronaviruses have 4 structural proteins, nucleocapsid, envelope, membrane and spike (S). S 
from both SARS-CoV-2 and SARS-CoV-1 uses angiotensin-converting enzyme 2 (ACE2) as 
the cell surface receptor (Hoffmann et al., 2020), ACE2 is expressed in a number of tissues, 
including epithelial cells of the upper and lower respiratory tracts. S consists of two subunits, 
S1 which mediates receptor binding and S2 responsible for viral and host cell membrane 
fusion (Walls et al., 2020; Wrapp et al., 2020). It is a dynamic structure capable of 
transitioning to a post-fusion state (Cai et al., 2020) by cleavage between S1 and S2 
following receptor binding or trypsin treatment. In most SARS-CoV-2 sequences a furin 









cleavage site attenuates disease in animal models (Johnson et al., 2020).  The S1 fragment, at 
the membrane distal tip of S, includes an N-terminal domain (NTD) and receptor binding 
domain (RBD). While both regions are immunogenic, the RBD contains the interacting 
surface for ACE2 binding (Lan et al., 2020). Although usually packed down against the top 
of S2, RBDs can swing upwards to engage ACE2 (Roy et al., 2020). Monoclonal antibodies 
(mAbs) recognize one or both of ‘up’ and ‘down’ conformations (Zhou et al., 2020; Liu et 
al., 2020). The S protein is relatively conserved between SARS-CoV-2 and SARS-CoV-1 
(76%), but the RBD and NTD are less conserved (74% and 50% respectively) than the S2 
domain (90%) (Jaimes et al., 2020). Conservation with MERS-CoV and the seasonal human 
coronaviruses is much lower (19-21%). Overall SARS-CoV-2 antibodies show limited cross-
reactivity even with SARS-CoV-1 (Tian et al., 2020). 
 
Previous studies of SARS-CoV-2 have indicated that most potent mAbs bind close to the 
ACE2 interacting surface on the RBD to block the interaction with ACE2 (Zost et al., 2020; 
Liu et al., 2020) expressed on target cells or disrupt the pre-fusion conformation (Huo et al., 
2020; Yuan et al., 2020a; Zhou et al., 2020). There has been intense interest in S for the 
development of protective SARS-CoV-2 vaccines or for therapeutic mAbs, several of which 
are in clinical evaluation and even being deployed under EUA (DeFrancesco, 2020).  
 
Here we characterize a panel of 377 human mAbs from recovered COVID-19 patients. We 
devise a generally applicable method combining biophysical competition measurements with 
a smaller number of crystallographic structure determinations, to pin-point the attachment 
site for all 80 mAbs that bind the RBD. The resulting map shows that the antibody footprints 
cover the majority of the RBD surface, grouping into five epitopes by cluster analysis. In 









RBD, by X-ray crystallography or cryo-electron microsc py (cryo-EM). These include many 
of the most potently inhibitory antibodies, all RBD-binders except for a single N-terminal 
domain binder. We analyse the modes of binding for antibodies with several public heavy 
chain (HC) V-regions. Of these some engage identical sites through conserved HC CDR1 and 
CDR2 (H1, H2) interactions, whilst others use variable length HC CDR3s (H3) to bind at 
different points. We find that shuffling the light chain pairing within one of these families 
leads to tighter binding. Other potently neutralizing antibodies have novel interaction sites 
and several of these bear somatic mutations that create N-linked glycosylation sites in H1-H3 
(Zhang et al., 2016). By studying the valency of antibody binding to virus particles we show 
that some of the most potent antibodies can neutralise at low receptor occupancies. The most 
potent mAbs neutralize the virus in the low picomolar range and show both prophylactic and 
therapeutic activity in a stringent murine model of SARS-CoV-2 pathogenesis. 
 
Results  
Characterization of mAbs 
We studied a cohort of 42 patients who had proven SARS-CoV-2 infection diagnosed by 
qRT-PCR (Table S1). Patients were recruited using the ISARIC protocol following informed 
consent and recalled following convalescence (31-62 days). ELISAs were performed against 
full-length stabilized S protein (Wuhan-Hu-1 strain, MN908947) where residues 986 and 987 
in the linker between two helices in S2 were mutated to a Pro-Pro sequence to prevent the 
conversion to the post-fusion helical conformation (Walls et al., 2020; Wrapp et al., 2020), 
RBD (aa 330-532) or N protein (Figure S1A). As has been described previously, antibody 
titres varied between patients, and there was a strong correlation between neutralization titre 











To generate mAbs, two strategies were used. First, IgG expressing B cells were sorted, 4 cells 
per well, cultured with IL-2, IL-21 and 3T3-msCD40L cells for 13-14 days, and supernatants 
were tested for reactivity to S protein; positive clones were identified by RT-PCR (Figure 
S2A). In a second method, B cells were stained with labelled S or RBD proteins, and single 
positive cells were sorted and subjected to RT-PCR (Figure S2B). Cell recovery was higher 
in the severe COVID-19 cases (Figure S1C), and in total we isolated mAbs from 16 patients 
(9 mild, 7 severe). 
 
377 antibodies were produced, which reacted to full length S by ELISA. MAbs were further 
screened for reactivity to S1 (34%), S2 (53%), RBD (21%) and the NTD (11%), with the 
remaining 13% reactive only to full-length trimeric spike (Figure S3A). Analysis of antibody 
sequences revealed low levels of somatic mutation of germline sequences for both heavy 
(mean 4.11 ± 2.75 amino acids) and light chains (mean 4.10 ± 2.84 amino acids) (Figure 
S3B). In general, responses within and between individuals were highly polyclonal with 
diverse V-gene usage (Figure S3C).  We tested cross-reactivity of the 377 anti-S antibodies 
generated from SARS-CoV-2 patients to full-length S proteins from all human alpha and 
beta-coronaviruses (Figure 1A). Cross-reactivity was observed with SARS-CoV-1 (52%), 
MERS (7%), OC43 (6%), HKU1 (7%), 229E (1%), and NL63 (1%). However, for antibodies 
recognising RBD, cross-reactivity was restricted to SARS-CoV-1, the RBD of which shares 
74% sequence identity with SARS-CoV-2, much more than the other human CoVs (19-21%). 
Antibodies cross-reacting between the RBDs of SARS-CoV-2 and SARS-CoV-1 showed 
similarly low levels of germline mutation to the whole pool of S reactive antibodies. 
However, for antibodies cross-reacting between SARS-CoV-2 and the four seasonal 








S3D). One plausible explanation for the increase in germline mutation in the cross-reactive 
clones is that they were selected from the memory pool of seasonal coronavirus-specific B 
cells, rather than generated de novo after SARS-CoV-2 infection.  
 
Neutralization activity of SARS-CoV-2 mAbs  
Next, we investigated the neutralizing activity of all 377 mAbs using a focus reduction 
neutralization test (FRNT) using Vero cells. Only 5% of non-RBD mAbs showed 
neutralizing activity (IC50 < 10 µg/ml), whereas 60% of RBD-specific mAbs showed 
neutralizing activity (Figure 1B) consistent with previous studies of SARS-CoV-1 and 
SARS-CoV-2 (Barnes et al., 2020).  
 
In total, 19 of 80 anti-RBD antibodies yielded IC50 levels of < 0.1 µg/ml (Figure 1C), which 
we define as potent neutralizers. FRNT50 values for a selection of antibodies is shown in 
Table S2. A number of antibodies outside the RBD had weak neutralizing activity (IC50
values of 0.29-7.38 µg/ml). MAb 159, which binds to the NTD (see below), was one of the 
most potent inhibitory antibodies we obtained with an IC50 of 5 ng/ml. 
 
We measured the ability of anti-RBD mAbs to block interaction with ACE2 using a 
competitive ELISA. For antibodies showing neutralization, there was broad correlation 
between inhibitory potency and ACE2 blocking while NTD-binding mAb 159 did not block 
ACE2 binding (Figure 1C).  
 
To investigate the contribution of RBD binding antibodies to neutralization in polyclonal 
serum, we immunodepleted sera from 8 convalescent donors with recombinant RBD; 









performed in RBD-depleted and mock-depleted samples and showed the major contribution 
made by anti-RBD antibodies with 55-87% (mean 61.5%) of neutralisation due to RBD-
binders. Whilst some RBD epitopes (eg quaternary epitopes) may be resilient to RBD 
depletion this indicates that although the large majority of non-RBD antibodies do not 
neutralise, those that do have a substantive role in the polyclonal neutralizing response to 
SARS CoV-2 (Figure 1D). 
 
Mapping the RBD antigenic surface  
To acquire greater insight as to the mAb binding sites on the RBD, we measured pairwise 
competition between antibodies using biolayer interferometry (BLI) in a 96-well plate 
format. For 80 antibodies, 4404 of the 6340 non-diagonal elements of the square competition 
matrix were populated. The antibodies were classified into mutually competing groups using 
cluster analysis (Methods). We derived the topography of binding for all the tested antibodies 
directly from the competition data with the aid of existing structural data. We expanded the 
competition matrix to include 3 additional (‘external’) antibodies of known binding positions 
(Methods). The external antibodies and one structure determined in the present study were set 
to their known positions on a smoothened mesh derived from the solvent-accessible surface 
of the RBD. The remaining 79 antibodies were assigned randomly to a starting vertex on the 
mesh and their positions refined by iterative minimization of a simple target function to 
match observed competition (antibodies were modelled as competing spheres of 22 Å 
diameter, see Methods). Minimization was performed 1000 times using Monte Carlo 
sampling from random starting positions. The results with lowest residuals were filtered 
using cluster4x (Ginn, 2020). The final positions of the mAbs (Table S3) were taken as the 
sampled position with the lowest average square distance to all other sampled positions. This 









0.84). To assess the accuracy of the method, six antibodies whose positions we have since 
determined (see below), were compared with their predicted locations. The average error was 
7.6 Å. 
 
To facilitate interpretation of the results, we introduce a naming convention for the RBD by 
comparison with a human torso (Figure 2A). The predicted locations, covering most of the 
RBD surface, were classified into 5 groups using a clustering algorithm (Methods and 
cluster4x (Ginn, 2020)) (Figure 2B,C). The left flank cluster is distinct from the other 4 
clusters which show marked competition at their boundaries and interact sequentially from 
the left shoulder, neck, right shoulder to right flank. Competition was strongest between the 
left shoulder and neck, although the neck and right shoulder groups also cross-compete 
strongly (Figure 2C).  
 
The ACE2 binding site is shown in Figure 2D, and the positions of the 80 individual 
antibodies (plus externals) are depicted in Figure 2E. The neck cluster is the site of 
attachment of a number of antibodies possessing the public IGVH3-53 V-region (Yuan et al., 
2020b) and strongly overlaps the ACE2 binding site (Figure 2D-E). The left flank cluster 
includes previously determined structures EY6A, CR3022 and H014, all of which are 
reported to show neutralizing activity, but do not compete with ACE2 binding (Yuan et al., 
2020a; Huo et al., 2020; Zhou et al., 2020; Lv et al., 2020; Wrobel et al., 2020). Although the 
left flank is largely separated from the neck and shoulders, two mAbs (38, 178) nevertheless 
compete and are situated closer to antibodies of the left shoulder, compared to more isolated 
antibodies (1, 22, 177) (Figure 2E).  Some regions of the RBD are notable for the lack of 
antibody binding. The right and left flank clusters both interact with the neck and shoulder 









RBD. Antibodies are not seen against the N and C-termini, either because of incomplete 
presentation on the RBD or occlusion by other parts of the spike. 
 
Mapping neutralization 
In Figure 2F we map neutralisation to antibody position on the RBD. As expected, there is 
good correlation between overlap with the ACE2 footprint and neutralisation. However, there 
were examples of non-neutralizing antibodies that were good ACE2 blockers, and it is not 
clear why these antibodies performed poorly. From the competition data, we can identify 
pairs of non-competing potently neutralizing mAbs and, if we relax the potency threshold, 
triplets (Table S3).  Such combinations might prove useful in therapeutic cocktails (Baum et 
al., 2020;Dong et al., 2021).  
 
There are undoubtedly mechanisms of neutralization beyond ACE2 blocking, for instance 
159 binds the NTD, remote from the ACE2 binding site (see below).  Interestingly, 
antibodies co-locating with known neutralizing/protecting antibodies EY6A/H014 and S309 
(Huo et al., 2020; Zhou et al., 2020; Lv et al., 2020) in the left and right flank clusters 
respectively did not show appreciable neutralization in our assays. We speculate that our 
assay might not be equally sensitive to all mechanisms of neutralisation. 
 
Biophysical characterisation of selected antibodies 
We determined the kinetics of RBD attachment for 20 potent RBD binders (Table S2). KD 
values for Fab fragments ranged from 0.7 to 7.6 nM and off-rates, potentially associated with 
therapeutic efficacy, were in the order of 1,000-10,000 s (Ylera et al., 2013). We also 
characterised expression levels, thermostability, monodispersity, and freeze-thaw robustness 









65-80 °C (Walter et al., 2012) with more than 99% of the mass in a single species. A few 
appeared to have more complex unfolding pathways.  Nearly all were resilient to 20 freeze-
thaw cycles. 
 
Structural analysis of potent monoclonal antibodies - focusing on limited epitopes 
Based primarily upon the neutralization data (T ble S2), we selected antibodies for structural 
analysis. Structures of 19 complexes, usually of either Fabs bound to isolated RBD (8, by 
crystallography) or of individual Fabs or mAbs bound to trimeric spike (11, by cryo-EM) 
were determined. Antibody 159 binds to the NTD, whereas all other antibodies bind the RBD 
(Figures 3, 4A, 4B, Methods, Tables S5, S6, Figures S4, S5). Many RBD-binders (40, 150, 
158 and 269) bind to a tightly defined site in the neck cluster; 253, 316 and 384 bind more 
towards the front of the left shoulder; 88 binds towards the back of the left shoulder (although 
the footprints overlap); and mAb 75 binds at the right shoulder. The footprint of all of these 
antibodies overlap with that of ACE2 (Figures 3, S4, S5). 
 
By selecting antibodies that are the most potent in the FRNT assay, we omitted a large 
number of high affinity antibodies. This can be seen for instance in mAb 45, which had a KD 
of 0.018 µg /ml. This mAb showed weak neutralisation (IC50 2 µg /ml) and was predicted as 
mapping to the right flank (Figure 4C). Structure determination of 45 in a ternary complex 
with potent neutraliser 88 and RBD, revealed binding in the predicted position, a site not 
reported previously, adjacent to S309, an antibody with 79 ng ml−1 IC50 (Pinto et al., 2020; 
Piccoli et al., 2020) (Figures 3, 4C, 4D), demonstrating the value of the predictive mapping 
in identifying novel epitopes. 
 









Antibody 384 is our most potently neutralizing mAb with an IC50 of 2 ng/ml. Its binding 
mode is unlike any other SARS-CoV-2 antibody reported to date. It approaches the binding 
site on the top of the neck and left shoulder from the front with a relatively small footprint of 
630 Å2 (460 Å2 contributed by the heavy chain and 170 Å2 by the light chain). Although the 
orientation of 384 is similar to a group of previously reported Fabs (CV07-270, p2b-2f6 and 
bd629, (Kreye et al., 2020;  Ju et al., 2020; Du et al., 2020)), it is shifted 20 Å towards the left 
shoulder such that it does not contact the right chest (Figures 3, 4E). Only CDRs H2 and H3 
of the Fab 384 HC interact with the antigen (Figure 5A). It is unusual in that the 18-residue 
long H3 of Fab 384 binds across the top of the neck to reach the H3 binding site of the 
important IGVH3-53 group of Fabs (discussed below), making hydrophobic interactions 
from F104 and L105 at the tip to L455 and F456 of the RBD (Figure 5A). However, the 
main interactions that contribute to the binding affinity and orientation are with RBD residues 
482-486 on top of the shoulder. W107 of H3 makes strong π-i teractions with G485, Y59 of 
H2 contacts V483 and makes bifurcated H-bonds to the carbonyl oxygen of G482 and amino 
nitrogen of E484 which in turn salt-bridges with R52 and H-bonds to the side-chains of T57 
and Y59 (Figure 5A). E484-F486 also form a two-stranded antiparallel β-sheet with residues 
A92-A94 of L3 and make stacking interactions from F486 to Y32 of L1.  
 
Repeated usage of heavy chain V-regions demonstrates potent public responses 
The potent neutralisers we have identified frequently use public HC V-regions (shared by 
most people, compared to private, patient specific responses). Thus 5 potent mAbs use 
IGVH3-53 (bearing 3-10 non-silent mutations) (Figure 5B). IGVH3 antibodies have been 
observed before (e.g., B38, CB6 and CC12.3 (Wu et al., 2020b; Shi et al., 2020; Yuan et al., 
2020b; Hurlburt et al., 2020; Wu et al., 2020a; Du et al., 2020; Clark et al., 2020)). Our 








three members of the group, 150, 158 and 269 (the others are 175 and 222) and found that 
they bind almost identically at the back of the neck with similar footprints of about 800 Å2 
(Figures 3, S4B). The flat binding site of the RBD and the approach angle of the Fabs limit 
their H3 length (11 residues) and the number of contacts H3 makes with the RBD (Figure 
5C), which is compensated for by the interactions from H1, H2 and all CDRs of the light 
chain. Thus for 158, H3 makes four direct contacts (≤ 4 Å) and two hydrogen bonds to the 
RBD, whilst H1 and H2 together make 11 contacts and 6 hydrogen bonds, and the three LC 
CDRs contribute 6 contacts and 5 hydrogen bonds (Figure 5C). We note strong LC 
interactions with residue N501 of the RBD, which is mutated in recent variants (B.1.1.7, 
B.1.351, P.1). The H3 length matches that reported as optimal for this V-region (Yuan et al., 
2020b), and the H3 sequence of mAb 150 is strongly similar to that of CC1.12 (Yuan et al., 
2020b) (Figure S4A). Thus H1 and H2 determine the mode of engagement, as seen in 
previous studies of antibodies with this V-region (Figure S4C) (Yuan et al., 2020b).  
 
A second V-region which repeatedly confers potent (IC50 < 0.1µg/ml) neutralisation is 
IGVH1-58 (mAbs: 55, 165, 253 and 318). These have even fewer non-silent mutations (2 to 
5) and longer HC CDR3s (12-16 residues). Three antibodies (55, 165, 253) harbour a 
disulfide bond in their CDR3s, compete strongly with each other for binding and map to the 
neck epitope, but do not compete with mAb 318. In mAb 253 the disulfide brackets a 
glycosylation sequon (see below). The crystal structure of a complex including Fab 253 
confirmed that it binds within the dominant neck epitope (Figure 3). In contrast competition 
mapping indicates that Fab 318 binds at the right shoulder epitope (Figure 2E). It appears 
that for this V-region the CDR3 is more critical to recognition and can switch binding to 











The final V-region with at least 2 potent neutralizers is IGHV3-66, which was found a total 
of 5 times with 2 potent neutralizers (282 and 40). These two (with rather few mutations from 
germline and CDR3 lengths 12 and 13 respectively) compete strongly. Once again, we 
determined a complex structure for one (Fab 40) and demonstrated that, as expected from the 
competition data, this antibody binds squarely in the dominant neck epitope, almost 
indistinguishable from those using IGHV3-53 (Figure 5D). One IGHV3-66 mAb (398) has a 
much longer H3, 21 residues, and is predicted to bind on the edge of the neck epitope (Figure 
2E). 
 
IGHV3.11 is found in the most potent neutraliser, 384 but is also used by CV07-270 (Kreye 
et al., 2020).  CV07-270 is swung forward and sideways (compared to 384, Figure 4E) so 
that it does not compete with ACE2 binding, suggesting that the potency of 384 derives from 
the extended H3 interaction which reaches across the ACE2 binding site. 
 
Whilst IGHV3-30 is found in 11 RBD binders, none are potent neutralisers. H3 lengths for 
IGHV3-30 RBD binders vary from 12 to 20 residues, suggesting they bind at different sites, 
as confirmed by the structures of two representatives, 75 (in a ternary complex with 253) and 
45 (in a ternary complex with 88) (Table S5). 75 binds on the right shoulder and overlaps the 
ACE2 binding site (Figure 3), however the only HC-RBD contact is via the extended 20 
residue H3, whereas the bulk of the interaction is with the LC, outside of the ACE2 footprint, 
and ACE2 binding could likely displace the extended H3 loop (Figure 5E). 45, with an H3 
length of 14 residues, binds differently, well away from the ACE2 binding site on the left 









the mode of binding is modulated by H3 and not focused on a region overlapping the ACE2 
site.  
 
In summary, the major public V-regions used by potent antibodies generally target the neck 
epitope, usually with a common mode of binding dictated by the V-region (although they can 
occasionally switch epitopes), but this is not true for weaker neutralisers. This likely explains 
the overwhelming representation of a common mode of binding at the neck epitope in the 
structures determined to date (Figure S4C). 
 
Light chain mixing can increase neutralization titre 
For the three potent anti-RBD antibody clusters where >2 members shared the same IGVH 
(IGHV3-53, IGHV1-58 and IGHV3-66), we performed a mixing experiment, where each 
IGVH was matched with all the IGVL within that cluster (Figure 6A). Chimeric antibodies 
were expressed and neutralizations were performed and compared with the original mAb 
clone. Unexpectedly, we found a 10-fold increase in neutralization titres when the heavy 
chain of mAb 253 (IGVH1-58, IGVK3-20) was combined with the light chains of mAbs 55 
and 165, which are also (IGVH1-58, IGVK3-20) but contain the IGKJ1 region in contrast of 
IGKJ2 in mAb 253 (Figure 6B). Remarkably the sole difference in contact residues is a Trp 
for Tyr substitution in mAbs 55 and 165 (Figure 6C). Structural analyses of Fab-complexes 
with RBD reveals the large hydrophobic tryptophan side chain stabilising a hydrophobic 
region of the antibody and nestled against the key hydrophobic region (E484-F486) of the 
RBD used by many potent neutralisers, whilst the smaller tyrosine side chain makes fewer 
contacts. 
 









Although 15-25% of IgGs bear N-linked glycans in their variable regions, sometimes with 
impact on antigen binding, this finding is relatively poorly studied at the molecular level 
(Wright et al., 1991; van de Bovenkamp and Hafkenscheid, 2016). Of 80 RBD-binding 
antibodies described here, 14 (17.5%) contain glycosylation sequons arising from somatic 
mutations in their variable region. For 8 mAbs (1, 88, 132, 253, 263, 316, 337, 382) the 
sequons are in the HC and for 5 they lie in a CDR. Several of the HC mutations, but none of 
the LC mutations, are in potently inhibitory antibodies (neutralization IC50 < 0.1 µg/ml). Two 
of these (88 and 316) could be de-glycosylated without denaturation, and BLI analysis 
showed that this had negligible effect on RBD/Fab affinities (KD = 0.8/1.2 nM and 1.0/2.0 
nM, de-gylcosylated/glycosylated respectively for 88 and 316), although the on-rate was a 
little faster in the absence of sugar (e.g. 3.8x105 1/Ms compared to 1.4x105 1/Ms for mAb 88. 
However, mutations that eliminate glycosylation had a deleterious effect on neutralisation for 
these two and for the 253H165L chimera (Figure S6). Structures were therefore determined 
for mAbs 88, 316 and 253 in complex with RBD and with spike (Figures 3, 6D, S6, Tables 
S5, S6).  
 
Antibodies 88 and 316 contain glycosylation sites in H1 (N35) and H2 (N59) respectively. 
The crystal structure of the RBD-316 Fab complex at 2.3 Å resolution shows well-defined 
density for 3 glycans including an α1,6 linked fucose (Figure 6D and S6E). The structure of 
Fab 88 was determined in a ternary complex with 45 and RBD to 2.53 Å resolution (the ChCl 
domains of 88 were disordered but the VhVl domains had well defined density). Antibody 88 
binds to the back of the neck whereas 316 binds to the top of the neck, orientated radically 
differently, however the H3s of the two Fabs overlap well (Figure 6D and S6). The glycans 
of Fab 88 surround the back of the left shoulder like a necklace and those of Fab 316 sit on 









from HC, LC and glycans, respectively), whereas Fab 316 has a footprint of 950 Å2 (610 Å2, 
150 Å2 and 190 Å2 from HC, LC and glycans, respectively). As we describe above for mAb 
384, residues E484-F486 of the RBD make extensive interactions in these antibodies with 
residues from the 3 CDRs of the HC and L1 and L3 of the LC, thus for 316 the side chain of 
E484 H-bonds to N52 and S55 of H2 and Y33 of H1, G485 contacts W50 of H2, and F486 
makes strong ring stacking interactions with Y93 and W99 of L3 and Y34 of L1. This 
suggests E484-F486 constitutes a hot-spot of the epitope. These residues are accessible from 
a variety of different angles of attack, thus Fabs 384, 316 and 88 all interact with this region 
despite their markedly different poses on the RBD. In contrast, the H3 of 253 overlaps with 
the glycans of mAb 88 and the glycan of mAb 253 makes no direct interactions with the RBD 
(Figure 6D). 
 
In all cases the sugar is presented close to the top of the left shoulder, and in 2 out of 3 cases 
interacts directly but rather weakly with the antigen. The high frequency of sequon 
generation despite the rather few somatic mutations is intriguing and suggests positive 
selection. 
 
Binding in the context of the trimeric spike 
On isolated stabilised spikes the RBD is found in two orientations; ‘up’ and ‘down’ (Yuan et 
al., 2017; Roy et al., 2020). Both of these form an ensemble of conformations, up 
conformations vary by up to 20° (Zhou et al., 2020) and down can include a tighter packed 
‘locked’ conformation (Ke et al., 2020; Toelzer et al., 2020; Carrique et al., 2020; Xiong et 
al., 2020). The structures we see by cryo-EM have the RBD in either the classic up or down 
conformation (see Figure 7A), although antibody binding sometimes introduces small 









construct we have used is 1 RBD-up and 2-down. ACE2 can only attach to the up 
conformation, which is assumed to be less stable, favouring conversion to the post-fusion 
state. In our structures, we see Fabs 40, 150, 158 and the chimeras 253H55L and 253H165L 
binding to the spike in this one-up configuration. 253H55L also binds to the all-down 
configuration (1 Fab/trimer), as does Fab 316 (3 Fabs/trimer) and Fab 384 (1 Fab/trimer). In 
contrast, Fab 88 binds (3 Fabs/trimer) in the all-up configuration (Table S6 and Figure 7A).  
 
Although Fab 384, despite its high potency, predominantly binds only one RBD per trimer, 
analysis of different particle classes revealed some weak density decorating the other RBDs, 
also in the down position, while a subtle movement can be seen between the RBDs of 
different classes (Figure S5L). This could be attributed to a more favourable RBD 
conformation that can only be sustained by one RBD at a time. 
 
To visualise the binding of the highly potent mAb 159, it was necessary to incubate spike 
with 159 IgG (the Fab alone showed no binding). This revealed all three NTDs of the spike 
decorated by 159 with RBDs in either one-up or all-down configurations (Figure S5M). The 
159 binding site is ~15 Å from that of a previously reported NTD binder, 4A8 (Chi et al., 
2020), in which the CDR-H3 binds on the side of the NTD between the 144-153 and 246-258 
loops (Figure 7B). The CDR-H3 of 159 is 11 residues shorter than that of 4A8 (Chi et al., 
2020) and binds on the top centre of the NTD interacting with residues 144-147, 155-158, 
250-253 and the N-terminus of NTD. All 3 CDRs of the heavy chain contribute to a foot-
print of 515 Å2 on the NTD, whereas the light chain has little contact with the NTD (35 Å2), 
similar to 4A8 (Chi et al., 2020) (Figure 7B, C). 
 









We measured binding of full-length mAbs and Fab fragments to intact SARS-CoV-2 by 
ELISA and compared these with neutralization curves for antibodies for which we have 
structural information (Figure 7D and Table S7). For the anti-NTD mAb-159 binding of 
full-length and Fab to virions were nearly identical, in-line with NTDs on a trimer being too 
far apart to allow bivalent engagement (118 Å) (Figure 7C) and suggesting that mAb-159 
cannot span adjacent spike trimers at the virion surface. Interestingly, whilst IgG-159 is a 
potent neutraliser, Fab-159 has no neutralizing activity, suggesting that the Fc portion is 
crucial for activity, although the mechanism is not immediately apparent and does not 
involve blocking ACE2 interaction. 
 
Loss in binding and neutralisation with Fabs compared to IgG is quite modest for mAb-88, 
which attaches in the all-up conformation (Figure 7D and S6), but much more marked for 
mAbs that bind the all-down form of the spike (253, 316, 384). Thus mAb-384 showed 79-
fold less virus binding and a 486-fold loss of neutralisation activity when reduced to Fab, 
suggesting that both Fab arms are used when antibody interacts with virions and also 
highlights the exceptional KD of Fab-159, 2.5 to 81-fold better than the other Fabs depicted in 
Figure 7D and Table S7. Finally, we have used the following formula to estimate the 
relationship between antibody binding and neutralization: Percent occupancy = BMax* 
[Ab]/(Kd+[Ab]), where the BMax is percent maximal binding, [Ab] is the concentration of 
Ab required to reach 50% FRNT and Kd is the concentration of Ab required to reach half-
maximal binding. mAb-384 can achieve NT50 with an estimated average occupancy of 12% 
of the maximum available antibody binding sites on each virion, perhaps in part due to the 
avidity conferred by bivalent attachment (Table S7). Bivalent attachment to the down 
conformation may also lock all three RBDs, preventing attachment to ACE2. Some of the 









between the angle and position of attack of the antibody arm to the RBD and the constraints 
on flexibility in the system.  
 
In vivo efficacy 
We determined the efficacy of our most promising neutralizing human mAbs in vivo. We 
utilized the K18-hACE2 transgenic mouse model of SARS-CoV-2 pathogenesis wherein 
human ACE2 expression is driven by an epithelial cell specific, cytokeratin-18 gene promoter 
(McCray et al., 2007; Winkler et al., 2020). In this model, SARS-CoV-2 infected animals 
develop severe pulmonary disease and high levels of viral infection in the lung that is 
accompanied by immune cell infiltration and tissue damage (Winkler et al., 2020). Initially, a 
single 250 µg (10 mg/kg) dose of mAbs 40 and 88 were administered as prophylaxis by 
intraperitoneal injection 1-day prior (D-1) to intranasal (i.n.) challenge with 103 PFU of 
SARS-CoV-2. Passive transfer of mAb 40 or 88, but not an isotype control mAb (hE16), 
prevented SARS-CoV-2-induced weight loss (Figure S7A). In the lung homogenates of 
antibody 40 and 88 treated animals, no infectious virus was detected at 7 dpi, whereas 
substantial amounts were present in animals treated with the isotype control mAb (Figure 
S7B). Consistent with these results, viral RNA levels were reduced by approximately 10,000-
100,000-fold compared to isotype control mAb- treated animals (Figure S7C). In peripheral 
organs, including the heart, spleen, or brain viral RNA levels were reduced or undetectable in 
mAb 40 or 88 treated animals (Figure S7D-G). Moreover, levels of viral RNA at 7 dpi were 
markedly lower in the nasal washes of animals treated with mAbs 40 and 88 compared to the 
isotype control. 
 
To further evaluate the in vivo potency of our mAbs, we assessed the therapeutic activity of a 









protection were observed for individual mAbs, weight loss was significantly reduced in all 
animals treated with anti-SARS-CoV-2 mAbs at 6 and 7 dpi compared to the isotype control 
(Figure 7E). Whereas the lungs of isotype control mAb-treated animals had infectious virus 
levels of ~106 PFU/g of tissue, we barely detected infectious virus in animals treated with the 
mAbs 40, 88, 159, 384, or 253H55L (Figure 7F). Lung viral RNA levels at 7 dpi also were 
reduced in animals treated with mAbs 40, 159, 384, and 253H55L, although statistical 
significance was not achieved with mAb 88 despite mean reductions of ~100-fold (Figure 
7G). At sites of disseminated infection, notably the heart, spleen, and brain, all anti-SARS-
CoV-2 mAbs showed protective activity although mAbs 384 and 253H55L conferred the 
greatest reductions in viral RNA levels (Figure 7H-K). In nasal washes, mAbs 159 and 384 
showed the best ability to reduce viral RNA levels (Figure 7J). Collectively, these data 
demonstrate several mAbs in our panel can reduce infection in the upper airway, lower 
airway, and at distant sites when administered after infection.  
 
Discussion 
There is now a substantial database of antibody/antigen complexes for the SARS-CoV-2 
spike (84 PDB depositions as of 12 December 2020, including nanobody structures). The 
number of unique structures is smaller than this and the focus on potently neutralising public 
V-regions means that many have near identical binding modes (Figure S4).  Here we report, 
in contrast, a comprehensive analysis of anti-SARS-CoV-2 human mAbs. We measured the 
neutralisation ability of a set of 377 mAbs from a substantial cohort of COVID-19 patients 
and identified that 80 of these bind the RBD. For these, we have determined the binding sites 
of all 80 of these, using a combination of structural methods and a novel computational 
algorithm based on bio-layer interferometry competition measurements. This defines five 









continuous swathe running from the left shoulder to the neck, right shoulder and down the 
right flank of the torso whilst the fifth forms a more discrete site towards the left flank. These 
sites are widely distributed over the surface, however all but one of the 20 most potent (IC50 
<0.1µg/ml) neutralizing mAbs block receptor attachment to the neck. The single exception, 
mAb 159, binds the NTD and the mechanism of neutralisation is unclear. 
 
The large body of structural results allowed us  to dissect the high-resolution details of 
binding of the major classes of potent neutralisers that bind the RBD. Highly potent ACE2 
blocking mAbs map to two sites in the region of the neck and left shoulder, residues E484-
F486 bridge the epitopes and are accessible to Fabs binding from a variety of different angles 
of attack. It is notable that mutation F486L has been identified as a recurrent mutation 
associated with host-adaptation in mink (van Dorp et al., 2020) and likewise mutation E484K 
is found in the recently identified B.1.351 and P.1 lineages. We would expect these changes 
to impact on the binding of many of our most potent mAbs, including 384. A characterisation 
of the polyclonal antibody response would give insight into the potential for vaccine escape. 
 
There is a close association between potent neutralizers and public V-genes suggesting that 
vaccination responses should be strong (Yuan et al., 2020b).  Three public V-region genes are 
represented at least twice in our set, i) IGHV3-53: mAbs 150, 158, 175, 222 and 269, ii) 
IGHV1-58: 55, 165, 253 and 318 and iii) IGHV3-66: 282 and 40. The potent binders focus 
around the neck cluster, often with binding pose determined by the H1 and H2 loops. By 
switching light chains within these sets, we found that one (253) could improve functionally 
by an order of magnitude by using an alternate light chain to achieve better hydrophobic 









mAb, 384, adopts a unique pose, with a footprint extending from the left shoulder epitope 
across to the neck epitope via an extended H3.  
 
Despite the most potently neutralizing mAbs being close to germline, somatic mutations 
introduce N-linked glycosylation sites into the variable region of 17.5% of the potent 
neutralisers. These can contribute to the interaction with the RBD, and although they appear 
to have relatively little effect on affinity they significantly enhance neutralisation. The 
enhanced neutralisation we observe (along with other favourable properties, e.g. solubility, 
stability and mitigation of auto-antigen responses) warrant investigation of production 
methods to allow variable region glycosylated Fabs to routinely meet regulatory standards 
(Zhang et al., 2016). 
 
 We find that there is a correlation between Fab vs IgG binding/neutralisation and the mode 
of attachment to the prefusion spike as seen by cryoEM. Those antibodies which bind the 
spike in the down conformation appear to show a marked avidity boost to binding and 
neutralisation when Fab and full length IgG1 are compared (e.g. 316 and 384), suggesting 
that there is a relationship between the mode of attachment and neutralisation which is still 
not fully understood, as also seen from the potent neutralisation reported for antibodies that 
bind at the left and right flank (S309 and EY6A/H014 (Pinto et al., 2020; Zhou et al., 2020; 
Lv et al., 2020) epitopes that do not report strong neutralisation in the assay we use in this 
report.  
 
Finally, we demonstrate that the most potent antibodies we have identified can protect in an 
animal model, when administered prophylactically or therapeutically. The competition 









antibodies with non-overlapping epitopes which could create an immunotherapy with greater 
protection and resistance against mutation than a single monoclonal antibody.  
 
Limitations of the Study 
The mechanisms of neutralization by antibodies which bind to the NTD is not yet established 
and will be the subject of further study. The correlates of protection from SARS-CoV-2 
infection have not yet been established and the role of T cells needs further study. It is also 
the case that in vitro neutralization assays do not capture the contributions of Fcγ receptor 
interactions and complement activation which likely contribute to protection in vivo. The 
mapping methodology could be improved, for instance by covalently anchoring the antigen, 
by more complete sampling or better modelling of the antibody shape. It could also be made 
more routine by higher density testing (e.g. 384-well plates).  However, the approach could 
be applied equally to other data, e.g. surface plasmon resonance or ELISA to provide a 
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Figure 1. Characterization of SARS-CoV-2-specific mAbs. (A) Cross-reactivity of 299 
anti-spike (non-RBD) and 78 anti-RBD antibodies to trimeric spike of human alpha and beta- 
coronaviruses by capture ELISA. (B) Comparison of neutralization potencies (IC50) between 
anti-spike (non-RBD) and anti-RBD antibodies against authentic SARS-CoV-2 using focus 
reduction neutralization test (FRNT). The Mann–Whitney U test was used for the analysis 
and two-tailed P values were calculated. (C) Correlation between SARS-CoV-2 
neutralization and RBD:ACE2 blocking by anti-RBD antibodies. Antibodies with IC50 < 0.1 
µg/ml, 0.1-1 µg/ml and 1-10 µg/ml are highlighted in red, blue and orange, respectively. (D) 
Plasma was depleted of RBD-specific antibodies using Ni-NTA beads coated with or without 
RBD, then evaluated for SARS-CoV-2 neutralizing activity by FRNT assay (n = 8). Results 
are expressed as percent neutralization of control without plasma. The percentage of 
depletion of neutralizing antibodies for each sample tested is indicated at the top of each 
panel. 
 
Figure 2. RBD anatomy and epitope definition based on mapping results. (A) Pale grey 









terminus) to red (C-terminus) alongside grey surface depiction of RBD labelled to correspond 
to the adjacent torso (Torso Gaddi, Wikipedia, CC BY-SA 3.0, modified in Adobe 
Photoshop) used by analogy to enable definition of epitopes. (B) Cluster maps showing the 
output of the mapping algorithm with each spot corresponding to a ‘located’ antibody and 
colour-coded according to epitope. (C) BLI antibody data competition matrix (calculated 
values) output from cluster analysis showing the clustering into 5 epitopes. (D) RBD (grey) – 
ACE2 (purple) complex. RBD residues contacting ACE2 are shown in green. (E) Located 
antibodies mapped onto the RBD shown as a grey surface with the ACE2-binding site in 
green. The individual antibodies are depicted as spheres and colour coded as in (B), those 
central to this paper are labelled. (F) as for (E) but antibodies are colour coded according to 
their ability to neutralize see inset scale, red strongest neutralizers, blue weakest neutralizers.  
 
Figure 3 RBD complexes. The Fab–RBD complexes reported in this paper as determined by 
a combination of X-ray crystallography, with the exception of Fab 40 for which the Fab–
RBD has been excised from a cryo-EM structure of Fab 40 bound to the S protein. Panel (A) 
shows the front view and panel (B) the back view with the RBD surface shown in grey and 
Fabs drawn as cartoons with the heavy chain in red and the light chain in blue. The ACE2 
footprint on the RBD is coloured in green. 
 
Figure 4 Spike morphology and Fab binding. (A) Orthogonal views of the trimeric spike 
as a pale grey surface with one monomer depicted as a cartoon and rainbow coloured from 
the N- to the C-terminus (blue to red). (B) Surface depiction of the electron potential map for 
the Spike-mAb 159 complex determined by cryo-EM to 4.6 Å resolution. The Spike is shown 
tilted forwards and coloured in teal apart from the RBDs (grey) and the fragment of mAb 159 








sphere denoting the location of Fab 45 as predicted using the mapping algorithm reported 
here. (D) Grey surface depiction of the X-ray crystallographic structure of the observed 
RBD-Fab 45 complex. Fab 45 binds close to the predicted position but is slightly translated. 
The S309 Fab (the closest structure in the competition matrix on which the mapping 
algorithm was based) is shown superimposed. Both Fabs are depicted as a cartoon with the 
heavy chain in magenta and light chain in blue. (E) Orthogonal grey surface depictions of the 
RBD with Fab 384 bound and Fab CV07-270 superimposed onto the complex. These Fabs 
use the same heavy chain V-gene but bind differently. They are drawn as cartoons with the 
heavy and light chains for Fab 384 in magenta and blue and those for CV07-270 in pale pink 
and light blue respectively. 
  
Figure 5 Determinants of binding, CDR length (A). Fab 384 interaction: left panel 
overview of the interacting CDRs from the heavy chain (magenta) and light chain (cyan) with 
the RBD (grey surface). The interactions of the H3, H2 and L1 and L3 loops are shown in the 
adjacent panels. (B) The distribution of IGHV, IGKV and IGLV gene usage of anti-RBD 
antibodies. Antibodies are grouped and coloured according to their neutralization IC50 values. 
(C) Left panel overview of the CDR interactions for Fabs 150 (magenta), 158 (cyan) and 269 
(orange). Adjacent panels (top) show a close up of the H3 loop interactions for each of these 
antibodies retaining the same colour coding and the bottom panel shows the interactions of 
the L3 loop and also the sequence alignment for the loops. (D) Back and side views of the 
complex of Fab 40 and RBD (grey surface) with the Fab drawn as a cartoon with the heavy 
chain in magenta and the light chain in blue. Fab 158 (grey cartoon) is superimposed. Note 
despite Fab 40 using the IGVH3-66 public V-gene whilst 158 uses IGVH3-53 they bind 
almost identically. (E) Fab 75-RBD complex with the RBD drawn as a cartoon in magenta 









This antibody uses IGHV3-30 and is not a potent neutralizer. It can be seen that the only 
heavy chain contact is via the extended H3 loop.  
 
Figure 6 Determinants of binding, light chain swapping and glycosylation. (A) Table of 
sequences of MAbs 253, 55 and 165. (B) Neutralization activity of authentic SARS-CoV-2 
by the original mAb253, chimeric mAb253H55L and chimeric 253H165L (presented as IC50 
values). Immunoglobulin heavy and light-chain gene alleles are presented in the table. Data 
are from 3 independent experiments, each with duplicate wells and the data are shown as 
mean ± s.e.m. (C) The chimeric Fab 253H55L ((mAb 253 (IGVH1-58, IGVK3-20) heavy 
chain combined with the light chain of mAb 55 also (IGVH1-58, IGVK3-20) but containing 
the IGKJ1 region in contrast of IGKJ2 in mAb 253 in complex with the RBD here shown as a 
hydrophobic surface. The Fab is drawn as a ribbon with the heavy chain in magenta and the 
light chain in blue. This 10-fold increase in neutralization titre of this Fab compared to 253 
appears to come from the single substitution of a tryptophan for a tyrosine making a 
stabilizing hydrophobic interaction. (D) CDRs with sugar bound in the RBD complexes with 
Fabs 88 (top panel) sugar bound to N35 in the H1 loop, 316 (middle panel) sugar bound to 
N59 in the H2 loop and 253 (bottom panel) sugar bound to N102 in the H3 loop. Note Phe 
486, is marked by a diamond to enable the various orientations to be related.  
 
Figure 7 Determinants of binding, valency of interaction and in vivo studies. (A) Cryo-
EM Spike-Fab complexes showing different RBD conformations. The density for the Spike is 
shown in teal, the RBD in grey and Fab in orange. Left ‘all RBDs down’ conformation with 
Fab 316 bound, middle ‘one RBD up’ conformation with one Fab 158 bound, right ‘all RBDs 
up’ conformation with 3 Fab 88s bound. (B)  Potently neutralizing Fab 159 (cartoon 









transparent surface) and adjacent depicted with another NTD binding Fab (4A8) 
superimposed as a grey ribbon, the binding sites are separated by ~15 Å. (C) Fab 159 (HC 
magenta, LC blue) is drawn as a cartoon in its binding location on top of the NTD of the 
Spike which is drawn as a grey surface and viewed from the top (a full IgG is modelled onto 
one monomer showing that it cannot reach across to bind bivalently). (D) ELISA binding 
(blue) and FRNT neutralization (red) curves of ten full-length antibodies (solid lines) and 
corresponding Fab molecule (dash lines) against SARS-CoV-2. Data are from 2 independent 
experiments (mean ± s.e.m.). E-K. Seven to eight-week-old male and female K18-hACE2 
transgenic mice were inoculated by an intranasal route with 103 PFU of SARS-CoV-2. At 1 
dpi, mice were given a single 250 µg (10 mg/kg) dose of the indicated mAb by 
intraperitoneal injection. E, Weight change (mean ± SEM; n = 5-10, two independent 
experiments: two-way ANOVA with Sidak’s post-test: ns, not significant, * P < 0.05, ** P < 
0.01, **** P < 0.0001; comparison to the isotype control mAb treated group). F-K. At 7 dpi 
tissues were harvested and viral burden was determined in the lung (F-G), heart (H), spleen 
(I), nasal washes (J), and brain (K) by plaque (F) or RT-qPCR (G-K) assay (n = 7-11 mice 
per group; Kruskal-Wallis test with Dunn’s post-test: ns, not significant, * P < 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001). Dotted lines indicate the limit of detection. 
 
Figure S1. SARS-CoV-2 elicits binding and neutralizing antibodies against trimeric 
spike, RBD and NP proteins, related to Figure 1. (A) Plasma from donors with confirmed 
SARS-CoV-2 infection were collected at 1-2 months after onset of symptoms and tested for 
binding to SARS-CoV-2 spike, RBD and N proteins by capture ELISA. (B) neutralizing titres 
to authentic live virus. Data are representative of one experiment with 42 samples and 
presented as means ± s.e.m. (C) Comparison of the frequency of spike-reactive IgG 









indicate the median. Data are representative of one experiment with 16 samples. The Mann–
Whitney U test was used for the analysis and two-tailed P values were calculated (in B and 
C). 
 
Figure S2. SARS-CoV-2 antibody isolation strategies, related to Figure 1. Human 
monoclonal antibodies from memory B cells were generated using two different strategies. 
(A) IgG expressing B cells were isolated and cultured with IL-2, IL-21 and 3T3-msCD40L 
cells for 13-14 days. Supernatants were harvested and tested for reactivity to spike protein by 
ELISA. (B) Antigen-specific single B cells were isolated using labelled recombinant spike or 
RBD proteins as baits. The IgG heavy and light chain variable genes from both strategies 
were amplified by nested PCR and cloned into expression vectors to produce full-length 
IgG1antibodies. 
 
Figure S3. Specificity and sequence analysis of 377 human antibodies, related to Figures 
1, 2 and 5. (A) Epitope mapping of SARS-CoV-2 -specific antibodies against the RBD, 
S1subunit (aa 16–685) and S2 subunit (aa 686-1213) were evaluated by ELISA, and the 
NTD-binders were identified by cell-based fluorescent immunoassay. Antibodies interacting 
with none of the subdomains were defined as trimeric spike. The number in the centres 
indicate the total number of tested antibodies. (B) Frequency of amino acid substitutions from 
germline in SARS-CoV2-specific heavy and light chains (n = 377). (C) Repertoire analysis of 
antibody heavy and light chains of anti-S (Non-RBD) and anti-RBD antibodies. At the centre 
is the number of antibodies. Each slice represents a distinct clone and is proportional to the 
clone size. (D) Frequency of amino acid substitutions from germline in heavy and light 
chains of antibodies cross-reacting between SARS-CoV-2 and the 4 seasonal coronaviruses 









Figure S4. Crystal structures of the ternary complexes and overrepresentation of 
binding modes, related to Figures 4-7. (A) RBD-88-45, (B) RBD-253-75, (C) RBD-
253H55L-75 and (D) RBD-384-S309  complexes. (E) Sequence alignment for HC CDR3s 
using public V-region 3-53, antibodies are represented by a number (from this study) or by 
PBD code and a name. (F) Comparison of binding modes of 150 (orange), 158 (cyan), 269 
(magenta). (G) Superimposition of RBD-Fab complexes available in PDB (up to 21st Oct. 
2020). RBD is shown as grey surface, Febs as Cα traces with heavy chains in warm colour 
and light chains in cool colour. (H) The bound Fabs can be divided into four major clusters, 
neck (B38(7bZ5), CB6(7C01), CV30(6XE1), CC12.3(6XC4), CC12.1(6XC3), COV2-
04(7JMO), BD629(7CHC), BD604(7CH4), BD236(7CHB)), left shoulder (p2b-2f6(7BWJ), 
BD368(7CHC), C07-270(6XKP)), left flank (EY6A(6ZCZ), CR3022(6YLA), S304(7JX3), 
COVA1-16(7JMW)) and right flank (S309 (7JX3)), according to their binding modes on 
RBD. (I) Outliers that include right shoulder binders (REGN10987 (6XDG), COVA2-39 
(7JMP), CV07-250 (6XKQ), S2H14 (7JX3)). One Fab in the neck cluster is drawn as red and 
blue surface to show the relative position of the outliers. 
 
Figure S5. Cryo-EM Data, related to Figures 3, 4 and 7. Resolution and map quality at the 
RBD-Fab/IgG interface. (A-K) [left] Gold-standard FSC curve (FSC = 0.143 marked) 
generated by cryoSPARC for fab (or IgG in the case of 159)-spike structures [right] showing 
map quality at the antigen/antibody interface with 40, 88, 150, 158, 316, 384, 253H55L RBD 
up, 253H55L RBD down, 253H165L, 159 RBD down, 159 RBD up, respectively. 
Classification of Cryo-EM datasets show Spike heterogeneity for 384 and 159. (L) Gaussian 
filtered reconstructed volume (transparent grey) with refined spike (from two clusters of 384 









gaussian filtering, we are able to see slight evidence of one (right), or two (left) additional 
bound fabs. (M) Reconstructed volume for 159 in the RBD up (left) and down (right) 
positions, coloured by spike chain (blue, green, purple) and IgG (orange). The RBD in the up 
position is indicated by a red arrow. 
 
 
Figure S6. Importance of antibody glycosylation, related to Figure 6. (A-C) Effect of 
mutation of the Asn residue glycosylated in the heavy chains of antibodies 88, 253 and 316 
respectively. (D-F) |2Fo-Fc| electron density maps contoured at 1.2 σ showing the glycans at 
glycosylation sites at N35 of 88 (D) N59 of 316 (E) and N102 of 253 (F). (G)  Relative 
binding position and orientation of CDR-H3 and glycans between 316 (green) and 88 
(orange), and (H) between 316 and 253 (cyan). RBD is shown as a grey surface.  
 
Figure S7. Prophylaxis with mAbs 40 and 88 protects against weight loss and decreases 
viral burden, related to Figure 7. A-G. Seven to eight-week-old male and female K18-
hACE2 transgenic mice were given a single 250g dose of the indicated mAbs by 
intraperitoneal injection. One day later mice were inoculated by intranasal route with 103 
PFU of SARS-CoV-2. (A) Weight change (mean ± s.e.m; n=6, two independent experiments: 
two-way ANOVA with Sidak’s post test: ns, not significant, *P<0.05, ****P<0.0001; 
comparison is to the isotype control mAb treated group). B-G. At 7dpi tissues were harvested 
and viral burden was determined in the lung (B-C), heart (D), spleen (E), nasal washes (F) 
and brain (G) by plaque assay (B) or RT-qPCR (C-G) assay (n=6 mice per group. Kruskal-
Wallis test with Dunn’s post-test: ns, not significant, *P<0.05, **P<0.01, ***P<0.001). 











RESOURCE AVAILABILITY  
Lead Contact 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, David I Stuart (dave@strubi.ox.ac.uk). 
Materials Availability 
Recombinant proteins and antibodies generated in this study are available from the Lead 
Contact with a completed Materials Transfer Agreement.  
Data and Code Availability 
The coordinates and structure factors of the crystallographic complexes are available from 
the PDB with accession codes 7BEL, 7BEI, 7BEJ, 7BEK, 7BEN, 7BEO, 7BEM, 7BEH, 
7BEP (see Table S5). EM maps and structure models are deposited in EMDB and PDB with 
accession codes EMDB-12274, EMDB-12275, EMDB-12276, EMDB-12277, EMDB-12278, 
EMDB-12279, EMDB-12280, EMDB-12281, EMDB-12282, EMDB-12283, EMDB-12284 
and 7ND4, 7ND5, 7ND6, 7ND7, 7ND8, 7ND9, 7NDA, 7NDB, 7NDC, 7NDD respectively 
(see Table S5). The data that support the findings of this study are available from the 
corresponding authors on request. Code for the competition driven mAb mapping and 




EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Patient and blood samples 
Patients were recruited from the John Radcliffe Hospital in Oxford, UK, between March and 









recruited into the Sepsis Immunomics project [Oxford REC C, reference:19/SC/0296] 
ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections [Oxford 
REC C, reference 13/SC/0149]. Time between onset of symptoms and sampling were known 
for all patients and if labelled as convalescent patients were sampled at least 28 days from the 
start of their symptoms. Written informed consent was obtained from all patients. All patients 
were confirmed to have tested positive for SARS-CoV-2 using the reverse transcriptase 
polymerase chain reaction (RT-PCR) from an upper respiratory tract (nose/throat) swab 
tested in accredited laboratories. The degree of severity was identified as a mild, severe or 
critical infection according to recommendations from the World Health Organisation. Severe 
infection was defined for COVID-19 confirmed patients with one of the following 
conditions: respiratory distress with RR > 30/min; blood oxygen saturation < 93%; arterial 
oxygen partial pressure (PaO2) / fraction of inspired O2 (FiO2) < 300 mmHg; and critical 
infection was defined as respiratory failure requiring mechanical ventilation or shock; or 
other organ failures requiring admission to ICU. Comparator samples from healthcare 
workers or epidemiologically detected early clusters with confirmed SARS-CoV-2 infection 
who all had mild non-hospitalised disease were collected under the Gastro-intestinal illness in 
Oxford: COVID sub study [Sheffield REC, reference: 16/YH/0247]. 
Blood samples were collected and separated into plasma by centrifugation at 500 g for 10 
mins. Plasma was removed from the uppermost layer and stored at -80 °C. The PBMC layer 
was then gently suspended in the remaining plasma and RPMI media, and then isolated by 
Ficoll-Hypaque gradient centrifugation. All PBMC samples were stored in liquid nitrogen 
until use. 









Vero (ATCC CCL-81) cells and Vero-furin cells (Mukherjee et al., 2016) were  cultured at 
37 °C in Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 10 mM HEPES, and 100 U/ml of penicillin–streptomycin Spike ectodomain, 
human mAbs and Fabs were expressed in HEK293T cells cultured in FreeStyle™ 293 
Expression Medium (12338018, ThermoFisher) at 37 °C with 8% CO2. Nucleoprotein was 
expressed using 2-L cultures of Rosettagami2(DE3)pLysS bacteria (Novagen) in terrific 
broth medium containing 40 mg/L kanamycin, at 15˚C for 40 hrs following induction 
with Isopropyl ß-D-1-thiogalactopyranoside (1mM final concentration, Meridian Bioscience). 
For ACE2 and RBD, transient expression used Expi293F™ cells (Thermo Fisher, Cat# 
A14527) grown in Expi293™ Expression Medium (Thermo Fisher Cat# A1435103) in 
suspension with 8% CO2 at 30 or 37 °C and shaking at 130 rpm. For production of Spike 
protein for structural analysis, HEKExpi293F cells (Thermo Fisher Scientific) were 
transfected with the construct together with a phiC31 integrase expression plasmid and grown 
in adhesion roller bottles with the high glucose DMEM (Sigma) with 2% FBS for 6 days at 
30 °C. His-tagged RBD for structural analysis was expressed in a stable HEK293S cell line 
cultured in DMEM (high glucose, Sigma) supplemented with 10% FBS (Invitrogen), 1 mM 
glutamine and 1x non-essential amino acids at 37 °C. Cells were transferred to roller bottles 
(Greiner) and cultured in DMEM supplemented with 2% FBS, 1 mM glutamine and 1x non-
essential amino acids at 30 °C for 10 days for protein expression. For plaque assays Vero-
furin cells (Mukherjee et al.,2016) were cultured at 37 °C in Dulbecco’s Modified Eagle 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES, and 
100 U/ml of penicillin–streptomycin. 
Viral stocks 
SARS-CoV-2/human/AUS/VIC01/2020 (Caly et al., 2020) was grown in Vero (ATCC CCL-








80 °C. Viral titres were determined by a focus-forming assay on Vero cells. For mouse 
experiments, the 2019n-CoV/USA_WA1/2020 isolate of SARS-CoV-2 was obtained from 
the US Centers for Disease Control (CDC). Infectious stocks were propagated by inoculating 
Vero CCL81 cells and collecting supernatant upon observation of cytopathic effect; debris 
was removed by centrifugation and passage through a 0.22 µm filter. Supernatant was 
aliquoted and stored at -80 oC. 
 
Mouse experiments.  
Animal studies were carried out in accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were 
approved by the Institutional Animal Care and Use Committee at the Washington University 
School of Medicine (assurance number A3381–01). Virus inoculations were performed under 
anaesthesia that was induced and maintained with ketamine hydrochloride and xylazine, and 
all efforts were made to minimize animal suffering. 
 
Heterozygous K18-hACE C57BL/6J mice (strain: 2B6.Cg-Tg(K18-ACE2)2Prlmn/J) were 
obtained from The Jackson Laboratory. Seven to eight-week-old male and female animals 
were inoculated with 103 PFU of SARS-CoV-2 via intranasal administration. 
 
METHOD DETAILS 
Trimeric spike of SARS-CoV-2 
To construct the expression plasmids for SARS-CoV-2 spike protein, a gene encoding 
residues 1−1208 of the spike ectodomain with a mutation at the furin cleavage site (residues 
682-685) from RRAR to GSAS, proline substitutions at residues 986 and 987, followed by 








an 8XHisTag, was synthesized and optimized for mammalian expression (Wrapp et al., 
2020). An optimized coding sequence was cloned into the mammalian expression vector 
pHLsec. 
 
Trimeric spike of SARS-CoV, MERS-CoV, OC63-CoV, HKU1-CoV, 229E-Cov, NL63-CoV 
Expression plasmids were constructed using synthetic fragments coding for human codon-
optimized Spike glycoprotein sequences from CoV-229E (GenBank accession number 
NC_002645.1; amino acids 1–1113), CoV-HKU1 (GenBank accession number 
NC_006577.2; amino acids 1-1300), CoV-NL63 (GenBank accession number NC_005831.2; 
amino acids 1–1289), CoV-OC43 (GenBank accession number NC_006213.1; amino acids 
1–1297), CoV-MERS (GenBank accession number AFS88936.1; amino acids 1-1291) (Zhao 
et al., 2013), CoV-SARS1 (GenBank accession number AY27874; amino acids 11-1195) 
(Simmons et al., 2004) and CoV-SARS2 (GenBank accession number MN908947; amino 
acids 1-1208). Fragments were cloned in pHLsec vectors downstream of the chicken β-
actin/rabbit β-globin hybrid promoter and followed by a T4 fibritin trimerization domain, an 
HRV 3C cleavage site, a His-8 tag and a Twin-Strep-tag at the C terminus as previously 
reported by Wrapp et al. (Wrapp et al., 2020). 
Mutations coding for stabilising proline residues and to eliminate putative furin cleavage sites 
were inserted in each sequence as follows: For CoV-229E, TI>PP (aa 871-872); for CoV-
HKU1, RRKR>GSAS (aa 756-759) and AL>PP (aa 1071-1072); for CoV-NL63, 
RRSR>GSAS (aa 754-757) and SI>PP (aa 1052-1053); for CoV-OC43, AL>PP (aa 1070-
1071); for CoV-MERS, RSVG>ASVG (aa 748), RSAR>GSAS (aa 884-887) and VL>PP 
1060-1061; for CoV-SARS1, KV>PP (aa 968-969); for CoV-SARS2, RRAR>GSAS (aa 682-









DNA plasmids encoding the Strep-Tag-tagged spike proteins were transfected into HEK293T 
cells cultured in FreeStyle™ 293 Expression Medium (12338018, ThermoFisher) by PEI-
mediated transfection (MW: 25,000; branched: Sigma-Aldrich 408727) and incubated at 
37 °C for 7 days. Supernatants were then collected and cleared by centrifugation followed by 
filtration. CoV Spike protein trimers were affinity-purified using the Strep-Tactin®XT 
purification system (IBA Lifesciences) according to the instructions of the manufacturer. In 
the case of CoV-229E and CoV-NL63, the spike proteins were further purified by SEC 
(Superose 6 increase 30/100 GL column, GE Life Sciences; elution buffer: Tris 20mM, NaCl 
150mM, pH 7) to remove aggregates. The purity of the proteins was assessed by reducing 
(10% β-mercaptoethanol (β-ME)) and non-reducing sodium dodecyl sulfate polyacr l mide 
gel electrophoresis (SDS-PAGE) (~3 µg of protein). Purified proteins were concentrated in 
PBS, quantified by spectrophotometry, sterilized by filtration (Spin-X tube filter; 8160; 
Costar) and kept at −80 °C until use. 
Nucleoprotein (NP) 
The native SARS-CoV-2 nucleoprotein gene was cloned into a pET28a(+) vector (Novagen) 
downstream of the coding sequence for an N-terminal hexa-histidine tag and 3C-protease 
cleavage site (a gift from Fred Antson). Expression was carried out using 2-L cultures of 
Rosettagami2(DE3)pLysS bacteria (Novagen) in terrific broth medium containing 40 mg/L 
kanamycin, at 15˚C for 40 hrs following induction with Isopropyl ß-D-1-
thiogalactopyranoside (1mM final concentration, Meridian Bioscience). Upon centrifugation 
(10,000 x g; 20 minutes, 4 ˚C), pellets were resuspended in 60 ml H2O containing 10 mg/ml 
lysozyme (Sigma). After adding 70 ml buffer S (200 mM Tris pH 8.0, 2.5 M NaCl, 60 mM 
imidazole, 4 mM MgSO4, 0.2% triton X100) the suspension was sonicated (40% amplitude, 
10 seconds on-10 seconds off cycles, 20 min, 4 ˚C). Turbonuclease (3,000 units, Sigma) and 









4 ˚C) before purification over a 5-ml HisTrap column (Cytiva), using a 20 mM to 1 M 
imidazole gradient in 25 mM Tris pH 8.0, 1.5 M NaCl. Nucleoprotein-containing fractions 
were further purified over a Superdex 200 Increase 10/300 GL column (Cytiva) using a 25 
mM Tris pH 8.0, 1 M NaCl running buffer, followed by buffer exchange into phosphate-
buffered saline (PBS, Sigma) using PD-10 columns (Cytiva), and heparin-affinity 
chromatography using a 5-ml HiTrap heparin HT column (Cytiva) and a 0.15 - 1 M NaCl 
gradient in 40 mM sodium phosphate pH 7.4.  
 
Depletion of anti-RBD antibodies from plasma samples.  
Nickel charged agarose beads (nickel-nitrilotriacetic acid [Ni-NTA]; Qiagen) were washed 3 
times in PBS and then incubated overnight, rotating at 4 °C, with His-tagged RBD. Twenty 
micrograms of protein were added for every 50 µl of beads used in a final incubation volume, 
twice the bead volume. Beads incubated in the absence of RBD antigen were used as a beads-
only, mock control. The beads were then washed 3 times with PBS and precleared for 2h at 
RT with a pooled SARS-CoV-2 negative plasma at a dilution of 1 in 100 in an incubation 
volume 2 times the bead volume. Beads were then washed 3 times in PBS and incubated with 
the human plasma samples of interest at a dilution of 1:50 in PBS+, PBS containing an 
additional 150 mM NaCl and 20 mM imidazole, for 2h at 4 °C (50 µl beads per 200-µl 
sample). The remaining depleted samples were collected, filter sterilized, and tested for 
complete depletion by RBD direct ELISA. 
 
ACE2 and RBD 
Constructs are as described in Huo et al. 2020 (Huo et al., 2020) and production was as 










Isolation of human monoclonal antibodies from peripheral B cells by memory B cell 
stimulation 
To generate human monoclonal antibodies from peripheral blood B cells, CD22+ B cells 
were isolated from PBMCs using CD22 Microbeads (130-046-401; Miltenyi Biotec). Pre-
enriched B cells were stained with anti-IgM-APC, IgA-FITC and IgD-FITC. Double negative 
memory B cells (IgM-,IgA-/D-cells) were sorted by FACS and plated on 384-well plates at a 
density of 4 B cells per well. Cells were stimulated to proliferate and produce IgG by 
culturing with irradiated 3T3-msCD40L feeder cells (12535; NID AIDS Reagent Program), 
100 U/ml IL-2 (200-02; Peprotech) and 50 ng/ml IL-21 (200-21; Peprotech) for 13-14 days. 
Supernatants were harvested from each well and screened for SARS-CoV-2 binding 
specificity by ELISA. Lysis buffer was added to positive wells containing SARS-CoV-2-
specific B cells and immediately stored at −80 °C for future use in Ig gene amplification and 
cloning. 
 
Isolation of Spike and RBD-specific single B cells by FACS 
To isolate Spike and RBD-specific B cells, PBMCs were sequentially stained with 
LIVE/DEAD Fixable Aqua dye (Invitrogen) followed by recombinant trimeric spike-twin-
Strep or RBD-biotin. Cells were then stained with antibody cocktail consisting of CD3-FITC, 
CD14-FITC, CD56-FITC, CD16-FITC, IgM-FITC, IgA-FITC, IgD-FITC, IgG-BV786, 
CD19-BUV395 and Strep-MAB-DY549 (iba) or streptavidin-APC (Biolegend) to probe the 
Strep tag of spike or biotin of RBD. Spike or RBD-specific single B cells were gated as 
CD19+, IgG+, CD3-, CD14-, CD56-, CD16-, IgM-, IgA-, IgD-, Spike+ or RBD+ and sorted 
into each well of 96-well PCR plates containing RNase inhibitor (N2611; Promega). Plates 
were centrifuged briefly and frozen on dry ice before storage at −80 °C for future use in Ig 










Cloning and expression of SARS CoV2-specific human mAbs. 
Genes encoding Ig VH, Ig Vκ and Vλ from positive wells were recovered using RT-PCR 
(210210; QIAGEN). Nested PCR (203205; Qiagen) was then performed to amplify genes 
encoding γ-chain, λ-chain and κ-chain with 'cocktails' of primers specific for human IgG. 
PCR products of genes encoding heavy and light chains were joined with the expression 
vector for human IgG1 or immunoglobulin κ-chain or λ-chain (gifts from H. Wardemann) by 
Gibson assembly. For the expression of antibodies, plasmids encoding heavy and light chains 
were co-transfected into the 293T cell line by the polyethylenimine method (408727; Sigma), 
and antibody-containing supernatants were harvested for further characterization. 
 
Construction of Fab expression plasmids 
Heavy chain expression plasmids of specific antibodies were used as templates to amplify the 
first fragment, heavy chain vector include the variable region and CH1 until Kabat amino 
acid number 233. The second fragment of thrombin cleavage site and twin-Strep-tag with 
overlapping ends to the first fragment were amplified. The two fragments were ligated by 
Gibson assembly to make the Fab heavy chain expression plasmid. 
 
Construction of scFv antibody plasmid 
Heavy chain and light chain expression plasmids of specific antibodies were used as a 
template to amplify variable region gene of heavy and light chain respectively. Firstly, heavy 
chain gene products having the AgeI–SalII restriction enzyme sites were cloned into a scFv 
vector which is a modified human IgG expression vector which has a linker between the H 









chain gene products having NheI-NotI restriction enzyme site were cloned into scFv vector 
containing the heavy chain gene insert to produce scFv expression plasmids. 
 
Fab and scFv production and purification 
Protein production was done in HEK293T cells by transient transfection with 
polyethylenimine in FreeStyle 293 medium. For Fab antibody production, Fab heavy chain 
expression plasmids were co-transfected with the corresponding light chain. For scFv 
antibody production, scFv expression plasmid of specific antibody was used for transfection. 
After 5 days of culture at 37°C and 5% CO2, culture supernatant was harvested and filtered 
using a 0.22 mm polyethersulfone (PES) filter. Fab and scFv antibody were purified by 
Strep-Tactin affinity chromatography (IBA lifescience) according to the Strep-Tactin XT 
manual. 
 
Determination of plasma and antibody binding to recombinant protein by ELISA 
MAXISORP immunoplates (442404; NUNC) were coated with 0.125 µg of StrepMAB-
Classic (2-1507-001;iba) at 4 °C overnight and blocked with 2% skimmed milk in PBS (for 
plasma) or 2% BSA in PBS (for mAbs) for 1 h, plates were incubated with 50 µL of 10 
µg/mL double strep-tag recombinant spike of SARS-CoV-2, SARS-CoV, MERS-CoV, 
OC43-CoV, HKU1-CoV, 229E-CoV and NL43-CoV. After one hour, 50 µL of serially 
diluted plasma or mAbs was added, followed by ALP-conjugated anti-human IgG (A9544; 
Sigma) at 1:10,000 dilution. The reaction was developed by the addition of PNPP substrate 
and stopped with NaOH. The absorbance was measured at 405nm. To determine the binding 
to SARS-CoV-2 RBD, SARS-CoV-2 NP, SARS-CoV-2 spike S1 (40591-V08H; Sino 
Biological Inc) and SARS-CoV-2 spike S2 (40590-V08B; Sino Biological Inc), 









by 5 µg/mL of His-tag recombinant SARS-CoV-2 RBD, SARS-CoV-2 NP, SARS-CoV-2 
spike S1 and SARS-CoV-2 spike S2. The plasma endpoint titres (EPTs) were defined as 
reciprocal plasma dilutions that corresponded to two times the average OD values obtained 
with mock. EC50 of mAbs were evaluated using non-linear regression (curve-fit), GraphPad 
Prism 8 software. 
 
Whole Virus ELISA 
To determine the binding affinity of antibody to SARS-CoV-2 virus, virus was captured onto 
plates coated with mouse anti-SARS-CoV-2 spike (mAb31 with murine Fc) and then 
incubated with serial dilutions of SARS-CoV-2-specific human mAbs (full length IgG or 
Fab) followed by ALP-conjugated anti-human IgG (A8542, Sigma). The reaction was 
developed with PNPP substrate and stopped with NaOH. The absorbance was measured at 
405 nm. 
Results are expressed as the percentage of total binding, with 100% binding determined from 
the Ab concentration that gave maximum absorbance. GraphPad PRISM software was used 
to perform nonlinear regression curve-fitting analyses of binding data to estimate dissociation 
constants (Kd). Percent occupancy at IC50 was determined
 using the following formula: 
Percent occupancy = BMax* [Ab]/(Kd+[Ab]), where the BMax is percent maximal binding, 
[Ab] is the concentration of Ab required to reach 50% FRNT and Kd is the concentration of 
Ab required to reach half-maximal binding. 
 
Focus Reduction Neutralization Assay (FRNT) 
The neutralization potential of Ab was measured using a Focus Reduction Neutralization Test 
(FRNT), where the reduction in the number of the infected foci is compared to a no antibody 









2/human/AUS/VIC01/2020 (Caly et al., 2020) and incubated for 1 hr at 37 °C. The mixtures 
were then transferred to Vero cell monolayers and incubated for 2 hrs followed by the 
addition of 1.5% semi-solid carboxymethyl cellulose (CMC) overlay medium to each well to 
limit virus diffusion. A focus forming assay was then performed by staining Vero cells with 
human anti-NP mAb (mAb206) followed by peroxidase-conjugated goat anti-human IgG 
(A0170; Sigma). Finally, the foci (infected cells) were visualized by adding TrueBlue 
Peroxidase Substrate. The percentage of focus reduction was calculated and IC50 was 
determined using the probit program from the SPSS package. 
 
NTD Binding Assay 
MAbs were screened for binding to MDCK-SIAT1 cells expressing the N-terminal domain 
(NTD) of SARS-CoV-2 spike glycoprotein (MDCK-NTD). MDCK-NTD was created by 
stably transfecting MDCK-SIAT1 cells (ECACC 05071502) (Matrosovich et al., 2003) with 
cDNA encoding the SARS-CoV-2 NTD (amino acids VNLT…TLKS) fused to the 
transmembrane domain of haemagglutinin H7 (A/HongKong/125/2017) (EPI977395) at the 
C-terminus for surface expression using a second-generation lentiviral vector system. NTD 
expressing cells were FACS sorted using the FD7C mAb (Huang et al., 2020). In brief, 
MDCK-NTD cells were seeded at 3 × 104 per well in flat-bottomed 96-well plates (TPP) in 
high glucose DMEM containing 10% fetal bovine serum (FBS) at 37 ℃ overnight. The 
medium was then removed and washed with 2% FBS in PBS (PBS/2% FBS) twice. 10 µg/ml 
of mAbs supernatants from transfected 293T cells were added (50 µl per well) and incubated 
at room temperature for 1 h. A second antibody Goat anti-human IgG Fc specific-FITC 
(F9512, Sigma-Aldrich) diluted 1:300 in PBS/2% FBS was then added (50 µl per well) and 









fixed with 1% formaldehyde in PBS. The binding antibodies were detected by fluorescence 
intensities using a Clariostar plate reader (BMG, Labtech).  
 
ELISA based ACE2 binding inhibition assay 
For the ACE2 competition ELISA, 250 ng of ACE2 protein was immobilized to a 
MAXIXORP immunoplate and the plates were blocked with 2% BSA in PBS. In the 
meantime, serially diluted Ab was mixed with recombinant RBD-mFc (40592-V05H; Sino 
Biological) and incubated for 1 h at 37 °C. The mixtures were then transferred to the ACE2 
coated plates and incubated for 1 h followed by goat anti-mouse IgG Fc-AP (Invitrogen 
#A16093) at 1:2000 dilution. The reaction was developed by the addition of PNPP substrate 
and stopped with NaOH. The absorbance was measured at 405 nm. The ACE2/RBD binding 
inhibition rate was calculated by comparing to antibody-free control well. IC50 were 
determined using the probit program from the SPSS package. 
 
Spike protein production for structural analysis 
The stable cell line generation vector pNeoSec was used for cloning of the SARS-Cov2 Spike 
ectodomain comprising amino acids 27-1208 with mutations of the furin cleavage site 
(RRAR > GSAS at residues 682-685) and the PP (KV>PP at residues 986-987). At the N-
terminus, there is a twin StrepII tag and at the C-terminus fused with a T4 fibritin 
trimerisation domain, an HRV 3C cleavage site and a His-8 tag. The human embryonic 
kidney (HEK) Expi293F cells (Thermo Fisher Scientific) were transfected with the construct 
together with a phiC31 integrase expression plasmid as described earlier (Zhao et al., 2014). 
The polyclonal G418 resistant (1 mg/ml) cell population were used for protein production. 
Expi293F cells were grown in adhesion in roller bottles with the high glucose DMEM 









dialysed conditional media with prepacked 5 ml Columns of HisTrap excel (GE Healthcare 
Life Sciences). The protein was eluted in 300 mM imidazole containing phosphate-buffered 
saline (PBS) after a 20 mM imidazole PBS wishing step. The protein was further purified 
with a 16/600 Superdex 200 size exclusion chromatography with an acidic buffer (20 mM 
Acetate, 150 mM NaCl, pH 4.6) for the low pH Spike incubations, or a neutral buffer (2 mM 
Tris, 150 mM NaCl, pH 7.5). 
 
Production of RBD for structural analysis 
Stable HEK293S cell line expressing His-tagged RBD was cultured in DMEM (high glucose, 
Sigma) supplemented with 10% FBS (Invitrogen), 1 mM glutamine and 1x non-essential 
amino acids at 37 °C. Cells were transferred to roller bottles (Greiner) a d cultured in DMEM 
supplemented with 2% FBS, 1 mM glutamine and 1x non-essential amino acids at 30 °C for 
10 days for protein expression. For protein purification, the dialyzed media was passed 
through a 5 mL HisTrap Nickel column (GE Healthcare). The column was washed with 
buffer 20 mM Tris pH 7.4, 200 mM NaCl, 30 mM imidazole and RBD was eluted using 
buffer 20 mM Tris pH 7.4, 200 mM NaCl, 300 mM imidazole. A volume of 30 µl 
endoglycosidase H1 (~1 mg ml−1) was added to ~30 mg RBD and incubated at room 
temperature for 2 h. Then the sample was further purified with a Superdex 75 HiLoad 16/600 
gel filtration column (GE Healthcare) using 10 mM HEPES pH 7.4, 150 mM NaCl. Purified 
RBD was concentrated using a 10-kDa ultra centrifugal filter (Amicon) to 10.6 mg ml−1 and 
stored at -80 °C. 
 
Preparation of Fabs from IgGs 
Fab fragments were digested from purified IgGs with papain using a Pierce Fab Preparation 











Thermal stability was assessed using Thermofluor (DSF). Briefly, 3 µg of the Ab preparation 
was used in a 50 µl reaction containing 10 mM HEPES pH 7.5, 100 mM NaCl, 3X 
SYPROorange (Thermo Fisher). Samples were heated from 25-97 °C in a RT-PCR machine 
(Agilent MX3005p) and the fluorescence monitored at 25 °C after every 1 °C of heating. 
Melting temperatures (Tm) were calculated by fitting of a 5-parameter sigmoid curve using 
the JTSA software (P. Bond, https://paulsbond.co.uk/jtsa). Polydispersity was assessed by 
DLS using 10 µg of the Ab preparation in an UNCLE instrument (Unchained Labs). Freeze 
thaw experiments on 4 of the mAbs were performed with material at 1 mg/ml by flash-
freezing using LN2, thawing and centrifuging an aliquot (10 minutes at 20000 g) before 
measuring the absorbance at 280nm of the soluble fraction.  
 
Crystallization 
Purified RBD was combined separately with Strep-tagged Fab150, Fab58, scFv269 and 
Fab316 in a 1:1 molar ratio, with final concentrations of 13.2, 9.4, 12.7 and 13.0 mg ml-1, 
separately. RBD was combined with Fab45 and Strep-tagged Fab88, Fab75 and Fab253, and 
Fab 75 and Strep-tagged chimeric Fab 253H55L in a 1:1:1 molar ratio all with a final 
concentration of 7 mg ml−1, separately. Glycosylated RBD was combined with Fab 
S309(Pinto et al., 2020) and Fab384 in a 1:1:1 molar ratio with a final concentration of 
8 mg ml−1. These complexes were separately incubated at room temperature for 30 min. 
Initial screening of crystals was set up in Crystalquick 96-well X plates (Greiner Bio-One) 
with a Cartesian Robot using the nanoliter sitting-drop vapor-diffusion method, with 100 nl 
of protein plus 100 nl of reservoir in each drop, as previously described (Walter et al., 2003). 









condition C2, containing 0.09 M of NPS (nitrate, phosphate and sulphate), 0.1 M 
MES/imidazole pH 6.5, 10% (w/v) PEG 8000 and 20% (v/v) ethylene glycol and crystals 
also formed in Hampton Research PEGRx condition D11, containing 0.1 M imidazole pH 7.0 
and 12% (w/v) PEG 20000. Some good crystals of RBD-158 were obtained from Index 
condition C01, containing 3.5 M NaCOOH pH 7.0, while some crystals were formed in 
Proplex condition C1, containing 0.15 M (NH4)2SO4, 0.1 M Tris pH 8.0 and 15% (w/v) PEG 
4000 and further optimized in 0.15 M (NH4)2SO4, 0.1 M Tris pH 7.6 and 14.6% (w/v) PEG 
4000. Crystals of RBD-scFv269 complexed were obtained from Index condition F01, 
containing 0.2 M Proline, 0.1 M HEPES pH 7.5 and 10% (w/v) PEG 3350. Good crystals for 
the RBD-316 complex were obtained from Index condition G10, containing 0.2 M MgCl2, 
0.1 M bis-Tris pH 5.5 and 25 % (w/v) PEG 3350. Crystals of RBD-45-88 complex were 
obtained from PEGRx condition G12, containing 10% (v/v) 2-Propanol, 0.1 M Sodium 
acetate trihydrate pH 4.0, 22% (w/v) PEG 6000. Crystals of RBD-75-253 complex were 
obtained from PEGRx condition D8, containing 0.1 M BIS-TRIS pH 6.5, 16% (w/v) PEG 
10000. Crystals of RBD-75-253H55L were obtained from Index condition F5, containing 0.1 
M ammonium acetate, 0.1 M bis-Tris pH 5.5 and 17% (w/v) PEG 10000. For the RBD-S309-
384 ternary complex, good crystals were obtained from Morpheus condition H1, containing 
0.1 M amino acids (Glu, Ala, Gly, Lys, Ser), 0.1 M MES/imidazole/ pH 6.5, 10% (w/v) PEG 
20000 and 20% (w/v) PEG MME 550.  
 
X-ray data collection, structure determination and refinement 
Crystals were soaked in a solution containing 25% glycerol and 75% reservoir solution for a 
few seconds and then mounted in loops and frozen in liquid nitrogen prior to data collection. 
Diffraction data were collected at 100 K at beamline I03 of Diamond Light Source, UK. 









exposure time ranging from 0.004 to 0.01 s per frame, beam size 80×20 µm and 100% beam 
transmission. Data were indexed, integrated and scaled with the automated data processing 
program Xia2-dials or Xia2-3dii (Winter, 2010; Winter et al., 2018). For RBD-158 crystal 
form 2, RBD-316 and the ternary complexes of RBD88-45, RBD-253H55L and RBD-384-
S309 data sets of 360° were collected from a single frozen crystal each, and 720° of data 
from 2 crystals for RBD-150, RBD-scFv269, RBD-158 crystal form 1 and RBD-253-75.  
 
The structures were determined by molecular replacement with PHASER (Liebschner et al., 
2019) using search models of the RBD, VhVl and ChCl domains of a closely related Fab in 
sequence for each complex. Sequence corrections to the target Fabs from the search models 
and model rebuilding were done with COOT (Emsley and Cowtan, 2004). All the structures 
were refined with PHENIX (Liebschner et al., 2019) resulting in good R-factors and 
stereochemistry for most of  the structures except for RBD-88-45 and RBD-53-75 in each of 
which there is presence of translational NCS with vectors (-0.003 0.502 0.489) and (0.044, 0, 
0.5) and can only be refined to Rwork/Rfree of 0.250/0.285 and 0.242/0.284 to 2.53 Å and 2.50 
Å, respectively. The ChCl domains of Fab 88 in the RBD-88-45 complex are disordered. 
Data collection and structure refinement statistics are given in Table S5.   
 
Cryo-EM Grid Preparation 
For all Fab or IgG-Spike complexes, a 3 µL aliquot of S ~0.6 µm (determined by OD) with 
Fab (1:6 molar ratio) was prepared, aspirated and almost immediately applied to a freshly 
glow-discharged Cu support Cflat 2/1-200 mesh holey carbon-coated grid (high intensity, 20 
s, Plasma Cleaner PDC-002-CE, Harrick Plasma). Excess liquid was removed by blotting for 









100% reported humidity before plunge freezing into liquid ethane using a Vitrobot Mark IV 
(Thermo Fisher). 
 
Cryo-EM Data collection and processing 
40, 253H55L and 253H165L spike complexes: 
For sample-specific details, refer to Table S6.  
 
Movies were collected in compressed tiff format on a Titan Krios G2 (Thermo Fisher) 
operating at 300 kV with a K3 detector (Gatan) in super resolution counting mode using a 
custom version of EPU 2.5 (Thermo Fisher). A defocus range of 0.8-2.6 µm was applied with 
a nominal magnification of x105,000, corresponding to a calibrated pixel size of 0.83 Å/pixel 
and with a total dose of 43-47 e/ Å2, see Table S6.  
 
Two-times binned movies were then motion corrected and aligned on the fly using 
Relion(3.1) scheduler (Zivanov et al., 2018) with a 5 x 5 patch based alignment. CTF-
estimation of full-frame non-weighted micrographs was performed with the GCTF (1.06) 
(Zhang, 2016) module in cryoSPARC(v2.14.1-live) (Punjani et al., 2017). 
 
88, 150, 158, 159IgG, 316 and 384 spike complexes: 
Data for 88, 150, 158 were collected Titan Krios G2 (Thermo Fischer) operating at 300 kV 
with a K2 camera and a GIF Quantum energy filter (Gatan) with a 30 eV slit. For 159 (IgG), 
384 and 316 , data were collected as for 88, 150 and 158, except using a 20 keV slit. Rapid 
multi-shot data acquisition was set up using custom scripts with SerialEM (version 3.8.0 
beta) (Mastronarde, 2005)  at a nominal magnification of 165 kX, corresponding to a 









with a total dose of ~45-57 e-/Å2 applied across 40 frames. Motion and CTF correction of raw 
movies was performed on the fly using cryoSPARC live patch-motion and patch-CTF 
correction(Punjani et al., 2017).  
 
40, 253H55L, 253H165L, 88, 150, 158, 159 IgG, 316 and 384 complexes: 
Poor-quality images were discarded after manual inspection of CTF and motion estimations. 
Particles were then blob picked in cryoSPARC (Punjani et al., 2017)  and initially extracted 
with four times binning. After inspection of 2D classes, classes of interest were selected to 
generate templates for complete particle picking. Binned particles were then subjected to one 
to three rounds of reference free 2D classification followed by 3D classification with an ab-
initio derived model before further refinement and unbinning. 
 
For both 150 and 158, two data separate data collections were set up on the same grid, and 
refined particle sets from each collection were separated by exposure groups before being 
combined. For 150, a total of 77,265 exposure-group split particles were initially combined 
(51,554 from 4726 movies and 25,711 from 2079 movies), re-classified into five classes, and 
the two best classes (42,655 particles) subjected to further non-uniform refinement, with 
obvious density for Fab bound to one RBD in an ‘up’ conformation. Notably, discarded 
classes included a high proportion of undecorated S (28,463 particles, 4.4 Å reported 
resolution at GSFSC = 0.143, -43 Å2 B-factor).  
 
Classification using heterogeneous refinement in cryoSPARC was found to be generally 
poor, and, instead, 3D variability analysis was employed to try to better resolve full spike-Fab 
structures. Local refinements were also performed with masks focused around the Fab/RBD 









RBD/Fab interface and far inferior to the crystallographic maps. 3D variability analysis was 
found to be essential for isolating the RBD up and RBD down conformations for 159-IgG. 
Results from this are presented for 159-IgG and 384. Briefly, data were separated into eight 
clusters using the 3D variability analysis module with a 6 Å resolution filter and a mask 
around the RBD/Fab region. Masks were generated by initially rigid body fitting a model of 
the spike and a Fab into a refined map in Chimera before selecting an area of the model 
including the RBD and fab and using the ‘color zone’ module to crop out this desired part of 
the map. The resulting map was smoothed with a gaussian filter (Pettersen Ef Fau - Goddard 
et al., 2004), converted into a mask format using Relion3.1 ‘Mask Create’ before import into 
cryoSPARC. Resolution estimates quoted in the Table S6 were taken from Gold standard-
FSC (FSC = 0.143) reported in the local resolution module in cryoSPARC (Punjani et al., 
2017). 
 
Competition assay of antibodies 
Competition assay of anti-RBD antibodies was performed on a Fortebio Octet RED96e 
machine with Fortebio Anti-HIS (HIS2) Biosensors. 2 µg ml−1 of His-tagged RBD dissolved 
in the running buffer (10 mM HEPES, pH 7.4 and 150 mM NaCl) was used as the ligand and 
was first immobilized onto the biosensors. The biosensors were then washed in the running 
buffer to remove unbound RBD. Each biosensor was dipped into different saturating 
antibodies (Ab1) to saturate the bound RBD, except one biosensor was into the running 
buffer in this step, acting as the reference. The concentration of saturating antibodies used 
was 15 µg ml−1. Higher concentrations were applied if 15 µg ml−1 was not enough to obtain 
saturating. Then all biosensors were washed with the running buffer again and dipped into 
wells containing the same competing antibody (Ab2). The concentration of competing 









in this step were divided by the value of the reference channel to get ratio results of different 
Ab1-Ab2 pairs. Ratio result close to 0 indicated total competition while 1 indicated no 
competition. In total, 50 IgGs and 4 Fabs (Fabs 40, EY6A (Zhou et al., 2020), FD5D 
(unpublished) and S309 (Pinto et al., 2020)) were used as the saturating antibodies and 80 
IgGs as the competing antibodies. 
 
Competition mapping of antibodies 
Gross binning of antibodies: Competition values were prepared for cluster analysis and 
binning by capping all competition values between 0 and 1. Competition values between 
antibodies i and j were averaged with the competition value for j and i when both were 
available. Cluster4x (Ginn, 2020) was used to cluster antibodies into three distinct groups 
using single value decomposition on the matrix of competition values. 
 
Preparation of RBD surface and mesh: A surface of the receptor-binding domain was 
generated in PyMOL (The PyMOL Molecular Graphics System, Version 1.2r3pre, 
Schrödinger, LLC) from chain E of PDB code 6YLA. A mesh was generated and iteratively 
contracted and restrained to the surface of the RBD to provide a smoother surface on which 
to direct antibody refinement, reducing intricate surface features which could lead to 
unrealistic exploration of local minima. 
 
Fixing positions of antibodies with known structure: In order to provide an objective position 
for those antibodies of known structure (FD5D (unpublished), EY6A (Zhou et al., 2020), 
S309 (Pinto et al., 2020) and mAb  40), to reflect the occluded region, all non-hydrogen 
antibody atoms were found within 20 Å of any RBD atom, and likewise all RBD atoms 









lengths from all other members were identified and the midpoint of these two atoms was 
locked to the nearest vertex on the mesh. Solvent molecules were ignored, but in the case of 
S309, the glycan cofactor was included in the set of antibody atoms. 
 
The target function: On an evaluation of the target function, either all unique pairs of 
antibodies were considered (all-pairs), or only unique pairs where one of the antibodies was 
fixed (fixed-pairs), depending on the stage of the minimisation protocol.  Competition levels 
were estimated for each pair of antibodies as described by f(x) in Eq. 1 
where r is the working radius of the antibody, set to 11 Å, accounting for the approximate 
antibody radius.  The distance between the pair of antibodies at a given evaluation of the 
function is given by d in Angstroms. The target function was the sum of squared differences 
between the competition estimation and the competition value from SPR data. 
 
Obtaining a self-consistent set of refined antibody positions: Minimisation was carried out 
globally by 1000 macrocycles of Monte Carlo-esque sampling using LBFGS refinement. A 
random starting position for each antibody was generated by randomly assigning a starting 
vertex on the RBD mesh and the target function minimised for 20 cycles considering data 
points for pairs with at least one fixed antibody, followed by 40 cycles for all data points. 
Between each cycle, antibody positions were locked onto the nearest mesh vertex.  
Depending on the starting positions of antibodies, results were a mixture of well-refined and 
poorly refined solutions. Results were ordered in ascending target function scores. Positions 
of antibodies for each result was passed into cluster4x as dummy C-alpha positions (Ginn, 
2020). A clear self-consistent solution was enriched in lower target function scores and 









chosen as the sampled position which had the lowest average square distance to very other 
sampled position, and the RMSD calculated from all contributing antibody positions. 
 
Measurement of viral burden (in vivo experiments).  
Tissues were weighed and homogenized with zirconia beads in a MagNA Lyser instrument 
(Roche Life Science) in 1000 µL of DMEM supplemented to contain 2% heat-inactivated 
FBS. Tissue homogenates were clarified by centrifugation at 10,000 rpm for 5 min and stored 
at −80 °C. RNA was extracted using the MagMax mirVana Total RNA isolation kit (Thermo 
Scientific) on a Kingfisher Flex extraction robot (Thermo Scientific). RNA was reverse 
transcribed and amplified using the TaqMan RNA-to-CT 1-Step Kit (ThermoFisher). Reverse 
transcription was carried out at 48 °C for 15 min followed by 2 min at 95 °C. Amplification 
was accomplished over 50 cycles as follows: 95 °C for 15 s and 60 °C for 1 min. Copies of 
SARS-CoV-2 N gene RNA in samples were determined using a previously published assay 
(PubMed ID 32553273). Briefly, a TaqMan assay was designed to target a highly conserved 
region of the N gene (Forward primer: ATGCTGCAATCGTGCTACAA; Reverse primer: 
GACTGCCGCCTCTGCTC; Probe: /56-
FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/). This region was included in an 
RNA standard to allow for copy number determination. The reaction mixture contained final 
concentrations of primers and probe of 500 and 100 nM, respectively.  
 
Plaque assay.  
Vero-furin cells (Mukherjee et al., 2016)  were seeded at a density of 2.5×105 cells per well 
in flat-bottom 12-well tissue culture plates. The following day, medium was removed and 
replaced with 200 µL of 10-fold serial dilutions of the material to be titrated, diluted in 









added. Plates were incubated for 72 h, then fixed with 4% paraformaldehyde (final 
concentration) in phosphate-buffered saline for 20 min. Plates were stained with 0.05% (w/v) 
crystal violet in 20% methanol and washed twice with distilled, deionized water prior to 
plaque enumeration.  
 
Affinity determination using biolayer interferometry 
Octet RED 96e (ForteBio) was used to determine the binding affinities of antibodies with 
RBD or spike. Anti-RBD IgGs were immobilized onto AR2G biosensors (ForteBio) while 
RBD was used as the analyte with serial dilutions. For IgG159, spike was immobilised onto 
AR2G biosensors with IgG159 acting as the analyte with serial dilutions. Kd values were 
calculated using Data Analysis HT 11.1 (ForteBio) with a 1:1 global fitting model. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
ELISA Kd and EC50 values were estimated using nonlinear regression curve-fitting analyses
 
of binding data, Prism Version 8 software (GraphPad). The percentage of focus reduction 
was calculated and IC50 was determined using the probit program from the SPSS package. 
IC50 were determined using the probit program from the SPSS package. Neutralization 
potencies (IC50) between 2 groups of antibodies were compared using two-tailed Mann–
Whitney U test, Prism Version 8 software (GraphPad). BLI Kd values were calculated using 
Data Analysis HT 11.1 (ForteBio) with a 1:1 global fitting model. Statistical analysis of 
weight change and viral burden i  vivo were determined by two-way ANOVA with Sidak’s 
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• Map 377 mAbs: 19 of 80 recognizing the RBD are potent neutralizers; 1 potent NTD binder 
• 19 Fab-antigen complex structures; 80 mAbs mapped on RBD and clustered into 5 epitopes 
• Most potent mAbs are ACE2 blockers, neutralize with few ACE2s, some Fabs glycosylated 
• mAbs reveal unique examples of  NTD binding, RBD binding mode and LC optimization 
 
In brief 
Dejnirattisai et al. present an in-depth study of the human antibody response to SARS-CoV-2 
infection. By characterizing 377 human mAbs from recovered COVID-19 patients, and determining 
19 protein structures, they construct a map of antibody footprints on the RBD describe in great 
detail its antigenic anatomy. 
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